試す - 無料

Eyeing 20-20 Vision of Excellence

BioSpectrum Asia

|

BioSpectrum Asia Jan 2025

Dr Jogin Desai, Co-Founder & Chief Executive Officer, Eyestem Research

Eyeing 20-20 Vision of Excellence

A native of Ahmedabad and an expert in the field of drug development, Dr Jogin Desai incorporated his startup Eyestem Research in India, back in 2015, aiming to democratise access to cell therapy through a scalable cell therapy platform.

The journey of Eyestem started when Dr Desai met ophthalmologist Dr Rajani Battu (currently the Chief Medical Officer at Eyestem), in 2015, for a medical appointment that changed everything for both of them. Following the appointment, Dr Rajani introduced him to patients diagnosed with degenerative diseases of the eye and the terrible suffering they have to endure. He realised that dry age-related macular degeneration (AMD) is the largest cause of incurable blindness in the world for patients over 50 years. And this meant that for 196 million people suffering from this disease around the world, 40 million of which are in India, finding a cure is a need of the hour.

Eyestem, as a company, was initiated in late 2015 by Dr Jogin Desai, Dr Rajani Battu and Dr Dhruv Sareen, with a small project handed to a research team led by Dr Rajarshi Pal, then at Manipal Institute of Regenerative Medicine. A year later, Dr Desai approached Centre for Cellular and Molecular Platforms, C-CAMP, in Bengaluru, with the intention to incubate considering the state-of-the-art cell culture facilities and diverse funding and mentoring programmes available at C-CAMP. Dr Rajarshi Pal joined as a Co-Founder to incubate and lead the science.

BioSpectrum Asia からのその他のストーリー

BioSpectrum Asia

BioSpectrum Asia

The Race to Build Singapore's Biotech Unicorns

MIRXES, known for its work in early cancer detection and backed by A*STAR and the National University of Singapore, became Southeast Asia's first biotech unicorn when it listed on the Hong Kong Exchange in 2025.

time to read

5 mins

BioSpectrum Asia Feb 2026

BioSpectrum Asia

BioSpectrum Asia

"Neuroinflammation is not only a hallmark of Alzheimer's disease but a key pathological feature in other neurodegenerative disorders"

As dementia becomes the leading cause of death in Australia and Alzheimer’s disease continues to affect millions worldwide, the urgency for fundamentally new treatment strategies has never been clearer.

time to read

4 mins

BioSpectrum Asia Feb 2026

BioSpectrum Asia

Leprosy Isn't Over: South-East Asia's Unfinished Fight

As we commemorate World Leprosy Day on January 25, the global community is oldest diseases-has not yet been consigned to history.

time to read

2 mins

BioSpectrum Asia Feb 2026

BioSpectrum Asia

BioSpectrum Asia

"Absence of a widespread infectious disease emergency in 2025 has hindered progress in combating AMR"

After decades of incremental antibiotic innovation, antimicrobial resistance (AMR) is outpacing our ability to respond, and 2026 may mark a breaking point.

time to read

5 mins

BioSpectrum Asia Feb 2026

BioSpectrum Asia

BioSpectrum Asia

The Strategic Rise of India's Deep-Science Economy

India is emerging as a powerful hub for deep science and biotechnology, driven by favourable geopolitics, a large domestic market, strong pharmaceutical and chemicals infrastructure, and supportive government policies.

time to read

4 mins

BioSpectrum Asia Feb 2026

BioSpectrum Asia

BioSpectrum Asia

Japan strengthening biopharma capabilities

Asia's biopharma landscape is shifting rapidly toward innovation, with countries such as South Korea, Singapore, India, and Taiwan advancing R&D capabilities.

time to read

7 mins

BioSpectrum Asia Feb 2026

BioSpectrum Asia

BioSpectrum Asia

Cancer Diagnosis, Accelerated by AI

Cancer remains a leading cause of death worldwide, with Asia bearing a disproportionate burden.

time to read

13 mins

BioSpectrum Asia Feb 2026

BioSpectrum Asia

BioSpectrum Asia

Beyond Companion Diagnostics: How Biomarkers and Digital Technologies Will Reshape Oncology Care in Asia by 2026

The oncology landscape in Asia stands at a critical juncture.

time to read

5 mins

BioSpectrum Asia Feb 2026

BioSpectrum Asia

BioSpectrum Asia

Pharma M&A set to boom in 2026

After years of unspectacular Mergers and Acquisitions (M&A) activity, 2025 recorded some of the largest pharma deals.

time to read

3 mins

BioSpectrum Asia Feb 2026

BioSpectrum Asia

BioSpectrum Asia

Seeing Opportunity in Ophthalmology

Asia-Pacific is emerging as one of the most active regions for ophthalmology innovation. In recent months, a wave of cross-border partnerships and licensing deals has underscored both the scale of unmet need in eye disease and the region's growing ambition to play a larger role in treatment development. From glaucoma and retinal disorders to dry eye disease and childhood myopia, companies across pharma, biotech, and medtech are increasingly accelerating clinical progress.

time to read

6 mins

BioSpectrum Asia Jan 2026

Listen

Translate

Share

-
+

Change font size